The San Francisco Bay Area area practice of physician (Dr. Raj Patel) has been IRB approved and has started baseline testing patients for the FDA open label Ampligen treatment study protocol (AMP 511).. Dr. Patel stated Ampligen can be started within a few weeks after a patient's baseline test results are OKed by Hemispherx Biopharma. He is the only physician in the SF Bay Area presently approved to administer Ampiigen. Persons interested in participating in the treatment study at his office in Los Altos, CA, and have the resources to pay for the costs involved (see below), contact: Dr. Raj Patel. AMP 511 Cost-Recovery treatment protocol requirements are expensive: * The total cost of Ampligen to a participant is approximately $2,500/month. * Ampligen is administered from 200mg or 400mg vials. The cost of the Ampligen alone, at the maximum therapeutic dose of 400mg twice per week, is $2,400 per 8 weeks, and is rarely covered by medical insurance. Some patients may require the lesser 200mg dose which is less expensive. * IV Infusion costs, administrative costs, and testing are extra and estimated at $2,000 per 8 weeks and are generally not covered by insurance. * Dr. Patel estimates it will take 18 months for most patients to achieve the full therapeutic and stabilization effects of Ampligen, and they should plan for that timeframe. Hemispherx has published a new study on the beneficial effects of Ampligen. According to the Hunter-Hopkins Center, Ampligen an experimental drug manufactured by Hemispherx Biopharma, is an anti-viral and immune modulator used to treat CFS. In a 1990-1992 placebo controlled study, approximately 80% of 45 CFS patients improved, and 50% improved significantly. A similar study in Belgium reported similar results. Several hundred persons have been treated with Ampligen, and thousands of doses of have been administered safely. Patient experiences with Ampligen can be read at: http://ampligen-treatment.blogspot.com/2010/01/my-ampligen-treatment-begins.html http://www.cfids-me.org/marys/ampcoda.html http://www.cfids-me.org/aacfs/ampligen.html http://theglassmountain.wordpress.com/category/ampligen/ https://docs.google.com/spreadsheet...FBkSHRPdkhZblRobzVWUTZUY3JGQ0E&hl=en_US#gid=0 * Dr. Patel has five years experience administering Ampligen. He is a fee-for-service provider. Patients pay the office directly for services at the time services are rendered, and submit his/her own claims to insurance. * Before being enrolled in the treatment protocol, patients will be tested for biomarkers to determine the likely response to Ampligen. * After a patient is determined appropriate for the study, they must remit a $1,000 deposit to the physician, for paperwork to be started. * Patients withdrawing during the paperwork period will forfeit their deposit. Patients who continue will have the $1,000 applied to their cost of Ampligen administration. Ampligen has a controversial history, including refusal of the FDA to approve retail marketing of the drug due to efficacy questions. Some patients state they've become worse on the drug. However, Ampligen has been clearly beneficial for a subset of ME/CFS patients. Some of the clinical factors that may identify these patients are: * Acute Viral Onset * 2-5A Synthetase/RNase L Up Regulation * Depressed Natural Killer Cell Cytotoxicity * Persistent Herpes Virus Infections (EBV, HHV-6, CMV, etc) Ampligen often initially causes dose dependent flu-like symptoms that can be significant. This has contributed to patient reports of Ampligen's adverse effects. These are not the only health risks from Ampligen. Titrating the Ampligen dose may help minimize side effects. Ampligen is administered intravenously twice per week, so people with fragile veins may have difficulty with infusions. IV ports are sometimes installed. Ampligen is administered under an experimental drug treatment protocol, and may be discontinued at any time without penalty by the participant, the FDA, the manufacturer, or the study principal investigator (usually the administering doctor). Before a person enrolls in the drug treatment protocol, the risks will be explained, and participants must sign a consent form. Persons that improve and consequently stop Ampligen for an extended period may eventually relapse after a unpredictable length of time. Some patients restart Ampligen if they start to relapse. Other sites administering the open label AMP 511 treatment study protocol include Dr. Peterson in Incline Village, NV, Dr. Lapp in Charlotte, NC, Dr. Enlander in NYC, Dr. Klimas in Miami, and Dr. Bateman in Salt Lake City. This notice is for informational purposes, and is not an offer or guarantee. Permission granted to repost.